Copy neutral loss of heterozygosity in 20q in chronic lymphocytic leukemia/small lymphocytic lymphoma

Cancer Genetics

Volumn 207, Issue 3, 2014, Pages 98-102

  Pei, Jianming ^a   Robu, Valentin ^a   Feder, Madelyn ^a   Cheung, Mitchell ^a   Neumann Domer, Erin ^a   Talarchek, Jacqueline ^a   Dulaimi, Essel ^a   Millenson, Michael M ^a   Testa, Joseph R ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Chromosome 20; Chromosome microarray analysis; Chronic lymphocytic leukemia; Copy neutral loss of heterozygosity; Imprinting

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; IBRUTINIB; LENALIDOMIDE; MICRORNA; RITUXIMAB;

ADULT; AGED; ARTICLE; ASXL1 GENE; CERVICAL LYMPHADENOPATHY; CHROMOSOME 20Q; CLINICAL ARTICLE; DISEASE COURSE; GENE LOCATION; GENE MUTATION; GENETIC ANALYSIS; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; LYMPH NODE BIOPSY; LYMPHADENOPATHY; LYMPHATIC LEUKEMIA; LYMPHOCYTOMA; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; PATHOGENESIS; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

CHROMOSOME 20; CHROMOSOME MICROARRAY ANALYSIS; CHRONIC LYMPHOCYTIC LEUKEMIA; COPY NEUTRAL LOSS OF HETEROZYGOSITY; IMPRINTING;

CHROMOSOMES, HUMAN, PAIR 20; HETEROZYGOTE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84899113369     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2014.02.005     Document Type: Article

References (32)

1. Dicker F., Schnittger S., Haferlach T., et al. Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: a study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood 2006, 108:3152-3160.
2. Mayr C., Speicher M.R., Kofler D.M., et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 2006, 107:742-751.
3. Lichter P., Cremer T., Borden J., et al. Delineation of individual human chromosomes in metaphase and interphase cells by in situ suppression hybridization using recombinant DNA libraries. Hum Genet 1988, 80:224-234.
4. Döhner H., Stilgenbauer S., Benner A., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. NEngl J Med 2000, 343:1910-1916.
5. Zenz T., Mertens D., Döhner H., et al. Importance of genetics in chronic lymphocytic leukemia. Blood Rev 2011, 25:131-137.
6. Calin G.A., Dumitru C.D., Shimizu M., et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002, 99:15524-15529.
7. Zenz T., Eichhorst B., Busch R., et al. TP53 mutation and survival in chronic lymphocytic leukemia. JClin Oncol 2010, 28:4473-4479.
8. Xu X., Johnson E.B., Leverton L., et al. The advantage of using SNP array in clinical testing for hematological malignancies-a comparative study of three genetic testing methods. Cancer Genet 2013, 206:317-326.
9. Pfeifer D., Pantic M., Skatulla I., et al. Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays. Blood 2007, 109:1202-1210.
10. Lehmann S., Ogawa S., Raynaud S.D., et al. Molecular allelokaryotyping of early-stage, untreated chronic lymphocytic leukemia. Cancer 2008, 112:1296-1305.
11. Gunnarsson R., Isaksson A., Mansouri M., et al. Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: a high-resolution genomic screening of newly diagnosed patients. Leukemia 2010, 24:211-215.
12. Hagenkord J.M., Monzon F.A., Kash S.F., et al. Array-based karyotyping for prognostic assessment in chronic lymphocytic leukemia: performance comparison of Affymetrix 10K2.0, 250K Nsp, and SNP6.0 arrays. JMol Diagn 2010, 12:184-196.
13. Gunnarsson R., Mansouri L., Isaksson A., et al. Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia. Haematologica 2011, 96:1161-1169.
14. Ouillette P., Collins R., Shakhan S., et al. Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. Blood 2011, 118:3051-3061.
15. Brown J.R., Hanna M., Tesar B., et al. Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia. Clin Cancer Res 2012, 18:3791-3802.
16. Schwaenen C., Nessling M., Wessendorf S., et al. Automated array-based genomic profiling in chronic lymphocytic leukemia: development of a clinical tool and discovery of recurrent genomic alterations. Proc Natl Acad Sci U S A 2004, 101:1039-1044.
17. Pei J., Jhanwar S.C., Testa J.R. Chromothripsis in a case of TP53-deficient chronic lymphocytic leukemia. Leuk Res Rep 2012, 1:4-6.
18. Malek S.N. The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia. Oncogene 2013, 32:2805-2817.
19. Dougherty M.J., Wilmoth D.M., Tooke L.S., et al. Implementation of high resolution single nucleotide polymorphism array analysis as a clinical test for patients with hematologic malignancies. Cancer Genet 2011, 204:26-38.
20. Boultwood J., Perry J., Pellagatti A., et al. Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia 2010, 24:1062-1065.
21. Gelsi-Boyer V., Brecqueville M., Devillier R., et al. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. JHematol Oncol 2012, 5:12.
22. Quesada V., Conde L., Villamor N., et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2012, 44:47-52.
23. Yamazawa K., Ogata T., Ferguson-Smith A.C. Uniparental disomy and human disease: an overview. Am J Med Genet C Semin Med Genet 2010, 154C:329-334.
24. Tuna M., Knuutila S., Mills G.B. Uniparental disomy in cancer. Trends Mol Med 2009, 15:120-128.
25. Gondek L.P., Haddad A.S., O'Keefe C.L., et al. Detection of cryptic chromosomal lesions including acquired segmental uniparental disomy in advanced and low-risk myelodysplastic syndromes. Exp Hematol 2007, 35:1728-1738.
26. Delhommeau F., Dupont S., Della Valle V., et al. Mutation in TET2 in myeloid cancers. NEngl J Med 2009, 360:2289-2301.
27. Jasek M., Gondek L.P., Bejanyan N., et al. TP53 mutations in myeloid malignancies are either homozygous or hemizygous due to copy number-neutral loss of heterozygosity or deletion of 17p. Leukemia 2010, 24:216-219.
28. Edelmann J., Holzmann K., Miller F., et al. High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. Blood 2012, 120:4783-4794.
29. Testa J.R., Kinnealey A., Rowley J.D., et al. Deletion of the long arm of chromosome 20 [del(20)(q11)] in myeloid disorders. Blood 1978, 52:868-877.
30. Heim S. Cytogenetic findings in primary and secondary MDS. Leuk Res 1992, 16:43-46.
31. Bastepe M., Jüppner H. GNAS locus and pseudohypoparathyroidism. Horm Res 2005, 63:65-74.
32. Jønsson V., Tjønnfjord G.E., Johannesen T.B., et al. Possible imprinting and microchimerism in chronic lymphocytic leukemia and related lymphoproliferative disorders. Transl Oncogenomics 2008, 3:15-20.